BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a fragment of a protective protein found in human gastric juice. It was first isolated in 1993 by Predrag Sikiric and colleagues at the University of Zagreb. Animal studies report acceleration of soft-tissue and gut healing across more than two decades of preclinical work.

The full sequence is Gly-Glu-Pro-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of 1419 Da. The parent protein, body protection compound, was characterized in stomach lining and gastric juice in the early 1990s as part of work on gastric mucosa defense. The 15-residue fragment turned out to be unusually stable. A 2011 paper by Sikiric and coauthors reported that the peptide survives more than 24 hours in human gastric juice without degradation, which is rare for short peptides and is the basis for oral research formats.

BPC-157 has carried several names over the years. PL-14736 was the designation used in the Croatian inflammatory bowel disease program. PCO-02, PL-10, and PLD-116 appear in older patent and trial documents. All refer to the same 15-amino-acid sequence.

BPC-157 is not a hormone agonist. It does not bind a single named receptor in the way GLP-1 agonists bind GLP-1R, or GHRH analogs bind GHRH receptors. The proposed mechanism is broader and harder to pin down.

The most consistent finding in the animal data is pro-angiogenic activity. Rat studies report upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and increased blood-vessel formation around injury sites. New blood supply matters for tendon healing, gut repair, and nervous-system injury, which is why the same molecule keeps appearing across very different injury models in the literature.

A second consistent finding is nitric oxide (NO) system modulation. Sikiric's group has described BPC-157 as "normalizing" NO production depending on context. A 2025 commentary in Pharmaceuticals flagged this framing as too convenient and called for independent multi-dose studies that examine whether NO upregulation has off-target effects, particularly on tumor angiogenesis.

Other pathways reported in preclinical work include FAK-paxillin complex activation (cell migration and adhesion), JAK-2 signaling, and ERK1/2 activity. Downregulation of NF-kB has been reported in injury settings. None of these mechanisms has been confirmed in human tissue. Human pharmacokinetic data is not published.

The Human Evidence

Three studies. Each is small. None is a randomized controlled trial.

Knee pain pilot (Lee and Padgett, 2021). A retrospective case series of 16 patients who received intra-articular BPC-157 injections for chronic knee pain. At 6 to 12 months, 14 of 16 (87.5%) reported significant pain relief. There was no placebo arm, no consistent underlying diagnosis, and no objective functional outcome measure.

Interstitial cystitis pilot (Lee et al., 2024). Twelve patients received bladder instillations of BPC-157. The published report describes 80 to 100 percent symptom resolution. The design is uncontrolled and the sample size limits conclusions to safety screening.

Intravenous safety pilot (Lee et al., 2025). Two adults received single IV doses of 10 mg and 20 mg. No serious adverse effects were reported. The sample size makes this hypothesis-generating, not safety-establishing.

Regulatory and Legal Status

On September 29, 2023, the FDA added BPC-157 to the Category 2 bulk drug substances list. Category 2 means the agency has reviewed the substance and concluded that it presents significant safety risk for compounding. No licensed 503A or 503B compounding pharmacy in the United States can legally prepare BPC-157 for patient use.

The FDA's Pharmacy Compounding Advisory Committee (PCAC) will meet on July 23 to 24, 2026 to reconsider BPC-157's status. Outside the compounding framework, BPC-157 has no FDA approval for any indication.

The World Anti-Doping Agency lists BPC-157 on its Prohibited List under section S0 (Non-Approved Substances). Use in competitive sport, in-competition or out-of-competition, is an anti-doping rule violation.

Animal Evidence Highlights

The rat literature spans more than 400 published papers across 35 years of work from the Sikiric laboratory and a small number of independent groups. Documented effects include accelerated repair of tendon, ligament, muscle, gastrointestinal mucosa, and blood vessels. Pro-angiogenic activity (VEGFR2 upregulation) and nitric oxide system modulation are the most consistent mechanistic findings. A 2025 scoping review in Pharmaceuticals flagged the BPC-157 literature for publication bias: more than 80 percent of indexed papers come from a single research group.

No standardized human dosing protocol exists for BPC-157. Animal studies have used a wide range of doses across oral, subcutaneous, intramuscular, and intraperitoneal routes. Translation to human dosing is not supported by published clinical pharmacokinetic data.

The three published human studies used the following protocols:

• Knee pain pilot (Lee and Padgett, 2021): Intra-articular injection. Specific dose not standardized across the 16-patient case series.
• Interstitial cystitis pilot (Lee et al., 2024): Bladder instillation. Specific dose not standardized across the 12-patient pilot.
• IV safety pilot (Lee et al., 2025): Single intravenous doses of 10 mg and 20 mg in two adults. No serious adverse effects reported.

Off-label adult research use circulates protocols of 250 mcg to 500 mcg subcutaneously, once or twice daily, over multiple weeks. Oral protocols of 250 to 500 mcg daily also circulate. These protocols are extrapolated from rat-study dose-per-kg scaling and online research-chemical forums rather than from controlled human pharmacokinetic studies.

The peptide is unusually stable in human gastric juice (more than 24 hours without degradation), which is the basis for oral research formats. Pharmacokinetic studies in rats by He et al. (2022) reported rapid metabolism into smaller peptide fragments and free amino acids, with half-life estimates in the minutes range. Human pharmacokinetic data is not published.

BPC-157 is on the FDA Category 2 bulks list, prohibiting compounding pharmacy production. It is on the WADA Prohibited List. Adult research use is not supported by published clinical safety guidance.

Animal toxicology studies on BPC-157 have not reported dose-limiting toxicity in rats, dogs, or mice within the doses tested. The He et al. (2022) pharmacokinetic paper documented widespread distribution into liver, kidney, and gut tissue followed by rapid clearance. Long-term studies in animals are limited and almost all come from the same laboratory.

The 2025 IV pilot in two adults reported no adverse effects at 10 mg and 20 mg single doses. The 2021 knee study and 2024 interstitial cystitis study reported no serious adverse events, though both were small and short. None of this constitutes a real safety database.

The 2025 Pharmaceuticals commentary raised three concerns that are not yet resolved. Angiogenesis modulation could theoretically support tumor vascularization in patients with undiagnosed or established malignancy. NO system stimulation at sustained high doses may produce off-target cardiovascular effects in humans that would not appear in short rat studies. And long-term safety data does not exist in any species at human-relevant doses across extended dosing periods.

None of these is documented harm. They are mechanistic flags that require properly designed human safety studies to address, and those studies have not been done. The FDA's Category 2 designation cited insufficient safety data as the basis for restriction, not documented harm in the field.

BPC-157 is most often compared to two other peptides marketed for soft-tissue repair: TB-500 (a thymosin beta-4 fragment) and Pentadeca Arginate (PDA), a stabilized BPC-157 analog.

TB-500 sits in a similar evidence position. It has substantial animal data on actin binding and cell migration but no published randomized human trials. Like BPC-157, it appears on the FDA Category 2 bulks list and the WADA Prohibited List.

Pentadeca Arginate is being marketed as a "next-generation" alternative to BPC-157 with improved stability. The published evidence base for PDA is smaller than for BPC-157 itself. Most claims rest on pharmacokinetic argument rather than independent comparative trials in animals or humans.

For practical purposes, all three sit in the same evidence and regulatory bucket: preclinical-dominant, no FDA approval, restricted from compounding, banned in sport.